150,317 members

Skip to content. | Skip to navigation


Difficult-to-treat multiple myeloma – NICE recommendation


Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.

Difficult-to-treat multiple myeloma – NICE recommendation

Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. NICE has recommended a new option for people with difficult-to-treat multiple myeloma.

Isatuximab, administered as an intravenous infusion, plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults.  It will be offered as a treatment option to those people who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed from their last treatment if they have had three previous forms of treatment.